Roughly 100 billion neutrophils have to be cleared from the body every day, and macrophages handle much of that work [13]. Divide by the 86,400 seconds in a day and the standing rate is about 1.16 million cells a second [17]. Neutrophils are short-lived, up to 24 hours with 12 more typical [9], so the disposal line never idles, and a shortfall in capacity accumulates rather than resolving. In older animals, most neutrophils that never meet a pathogen slide into senescence, a dysfunctional state in which they release chemicals that damage nearby cells and promote inflammation [11]. Counts rise with age, and the senescent share rises within them [12]. Andreasson is blunt about it: "Senescent neutrophils are killing our tissues" [16].
About 90% of circulating neutrophils end up in the liver, spleen and bone marrow, where other immune cells remove them [10]. Those same three organs appear on the list of tissues that held onto youthful characteristics after the receptor was blocked [18]. So do brain, kidney, colon and skeletal muscle [3], which the release does not describe as major disposal sites. Either local clearance matters in tissues with modest neutrophil traffic, or the benefit arrives through something circulating. The release does not settle which, and the distinction decides whether a candidate drug would need to cross into the brain at all.
The part of the design I would lean on first is the cell-type restriction. Tissue-resident macrophages settle into organs during fetal development and stay there for life, adapting to specialized local jobs [14]. That makes them an unusually clean population to manipulate, and disabling the receptor specifically in them, rather than everywhere [5], places the effect in those cells rather than in every other tissue where the same receptor sits.
The thing this doesn't tell you is how large any of it is. The announcement describes old mice as "leaner, stronger, sharper" and biologically younger without effect sizes, animal counts, the age at which the intervention started, or how long it ran [19]. Biologically younger also implies a clock, and no clock is named. Neither is a survival curve. The release points toward a drug strategy that might slow organ deterioration and extend healthy years [21], which is a healthspan claim and not a lifespan one, and the work was done in mice and human cells [1]. Human cells in a dish do not age inside a body.
What I find most interesting here is not the length of the organ list. It is that a clearance failure makes falsifiable predictions: if senescent neutrophil disposal is the mechanism, then the youthfulness should track clearance rate tissue by tissue, and it should break when you overload the system. Those are experiments someone can now run.
